Long-term Observational Study of Renal Outcome After Preeclampsia: Role of Soluble Fms-like Tyrosine Kinase-1(sFlt-1)/ Placental Growth Factor (PlGF) and Endoglin

Overview

Journal Ann Med Surg (Lond)

Publisher Wolters Kluwer

Specialty Medical Education

Date 2022 Jun 23

PMID 35734723

Authors

Thanaphan Thitivichienlert

Chadakarn Phaloprakarn

Thananda Trakarnvanich

Affiliations

Soon will be listed here.

Abstract

Introduction: Preeclampsia (PE) is an important complication of pregnancy that can lead to chronic kidney disease. Soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), the sFlt-1/PlGF ratio and endoglin are biomarkers for the differential diagnosis of PE and other diseases. We aimed to explore the correlation of these biomarkers with long-term renal function, blood pressure and the urine albumin/creatinine ratio (UACR) in PE patients.

Methods: 34 patients with PE were enrolled. Blood samples for sFlt-1, PlGF, endoglin and the urine albumin/creatinine ratio (UACR) were collected at the time of PE diagnosis (at 35-40 weeks' gestational age (GA) (87.50% of cases). After delivery, the patients were followed up at three months and one year to assess blood pressure, renal function and the UACR.

Results: Thirty-four PE patients were included, and 17 completed the study. The estimated glomerular filtration rate (eGFR) decreased significantly at three months and one year after follow-up (128.20 ± 10.34 to 120.75 ± 10.166 ml/min/1.73 m (p = 0.001) at three months and 126.71 ± 9.948 to 114.29 ± 11.274 ml/min/1.73 m (p < 0.001) at one year). The endoglin level correlated significantly with the eGFR level during PE, but there was no correlation of any biomarker with eGFR, blood pressure, or the UACR at one year.

Conclusion: Women with PE have a reduction of eGFR at three months and one year after the diagnosis of PE. Only endoglin is correlated with eGFR antepartum; however, it is not correlated with long-term renal function, blood pressure or the UACR.

Citing Articles

Preeclampsia pathophysiology and adverse outcomes during pregnancy and postpartum.

Bisson C, Dautel S, Patel E, Suresh S, Dauer P, Rana S Front Med (Lausanne). 2023; 10:1144170.

PMID: 37007771 PMC: 10060641. DOI: 10.3389/fmed.2023.1144170.

References

Inker L, Astor B, Fox C, Isakova T, Lash J, Peralta C . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63(5):713-35. DOI: 10.1053/j.ajkd.2014.01.416. View

Lopes van Balen V, Spaan J, Cornelis T, Spaanderman M . Prevalence of chronic kidney disease after preeclampsia. J Nephrol. 2016; 30(3):403-409. PMC: 5437128. DOI: 10.1007/s40620-016-0342-1. View

Tanabe K, Sato Y, Wada J . Endogenous Antiangiogenic Factors in Chronic Kidney Disease: Potential Biomarkers of Progression. Int J Mol Sci. 2018; 19(7). PMC: 6073618. DOI: 10.3390/ijms19071859. View

Leanos-Miranda A, Navarro-Romero C, Janet Sillas-Pardo L, Ramirez-Valenzuela K, Isordia-Salas I, Manuel Jimenez-Trejo L . Soluble Endoglin As a Marker for Preeclampsia, Its Severity, and the Occurrence of Adverse Outcomes. Hypertension. 2019; 74(4):991-997. DOI: 10.1161/HYPERTENSIONAHA.119.13348. View

Rudra C, Williams M . Monthly variation in preeclampsia prevalence: Washington State, 1987-2001. J Matern Fetal Neonatal Med. 2006; 18(5):319-24. DOI: 10.1080/14767050500275838. View

Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y . Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12(6):642-9. DOI: 10.1038/nm1429. View

. Poster Presentations. Nephrology (Carlton). 2021; 26 Suppl 1:32-55. DOI: 10.1111/nep.13944. View

Chappell L, Seed P, Briley A, Kelly F, Hunt B, Charnock-Jones D . A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol. 2002; 187(1):127-36. DOI: 10.1067/mob.2002.122969. View

Li C, Bethell H, Wilson P, Bhatnagar D, Walker M, Kumar S . The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis. 2000; 152(1):249-56. DOI: 10.1016/s0021-9150(99)00476-1. View

10.

Silva L, Coolman M, Steegers E, Jaddoe V, Moll H, Hofman A . Low socioeconomic status is a risk factor for preeclampsia: the Generation R Study. J Hypertens. 2008; 26(6):1200-8. DOI: 10.1097/HJH.0b013e3282fcc36e. View

11.

Lam C, Lim K, Karumanchi S . Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005; 46(5):1077-85. DOI: 10.1161/01.HYP.0000187899.34379.b0. View

12.

Magee L, von Dadelszen P . Pre-eclampsia and increased cardiovascular risk. BMJ. 2007; 335(7627):945-6. PMC: 2072036. DOI: 10.1136/bmj.39337.427500.80. View

13.

Vikse B, Irgens L, Leivestad T, Skjaerven R, Iversen B . Preeclampsia and the risk of end-stage renal disease. N Engl J Med. 2008; 359(8):800-9. DOI: 10.1056/NEJMoa0706790. View

14.

Reuvekamp A, Poulina I, Capello J, Duits A . Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol. 1999; 106(10):1019-22. DOI: 10.1111/j.1471-0528.1999.tb08107.x. View

15.

Levine R, Maynard S, Qian C, Lim K, England L, Yu K . Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350(7):672-83. DOI: 10.1056/NEJMoa031884. View

16.

Hirashima C, Ohkuchi A, Arai F, Takahashi K, Suzuki H, Watanabe T . Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res. 2006; 28(9):727-32. DOI: 10.1291/hypres.28.727. View

17.

Bersinger N, Odegard R . Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand. 2003; 83(1):37-45. View

18.

Silva L, Coolman M, Steegers E, Jaddoe V, Moll H, Hofman A . Maternal educational level and risk of gestational hypertension: the Generation R Study. J Hum Hypertens. 2008; 22(7):483-92. DOI: 10.1038/jhh.2008.22. View

19.

Cui L, Shu C, Liu Z, Tong W, Cui M, Wei C . Serum protein marker panel for predicting preeclampsia. Pregnancy Hypertens. 2018; 14:279-285. DOI: 10.1016/j.preghy.2018.01.009. View

20.

Wang I, Muo C, Chang Y, Liang C, Chang C, Lin S . Association between hypertensive disorders during pregnancy and end-stage renal disease: a population-based study. CMAJ. 2013; 185(3):207-13. PMC: 3576438. DOI: 10.1503/cmaj.120230. View